EPZM - Epizyme, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.89
+0.42 (+3.37%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close12.47
Open12.52
Bid11.30 x 800
Ask18.00 x 800
Day's Range12.34 - 12.89
52 Week Range5.14 - 21.40
Volume414,124
Avg. Volume858,745
Market Cap1.02B
Beta (3Y Monthly)3.30
PE Ratio (TTM)N/A
EPS (TTM)-1.97
Earnings DateMar 11, 2019 - Mar 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.56
Trade prices are not sourced from all markets
  • 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
    Zacks2 days ago

    5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

    Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

  • GlobeNewswire4 days ago

    New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Epizyme to File NDA for Tazemetostat in Follicular Lymphoma
    Zackslast month

    Epizyme to File NDA for Tazemetostat in Follicular Lymphoma

    Epizyme (EPZM) announces that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma.

  • Why Epizyme Stock Rose ~33% on January 4
    Market Realistlast month

    Why Epizyme Stock Rose ~33% on January 4

    Why Epizyme Stock Rose ~32% on January 4 ## Stock performance On January 4, Epizyme (EPZM) stock closed at $7.94, which represents ~32.78% growth from its prior close of $5.98 on January 3, 2019. On January 3, Epizyme stock fell 10.34% to reach $5.98 from its prior-day closing price of $6.67 on January 2. Epizyme stock fell from $12.55 at the close of market on December 29, 2017, to reach $6.16 on December 31, 2018, which was a ~51% decline in 2018. Epizyme’s price on January 4 is ~63% below its 52-week high of $21.4 on March 13, 2018. The company hit its 52-week low of $5.14 on December 24, 2018. ## Reason for stock price rise On January 4, Epizyme announced that it found a path for accelerated approval by the US FDA (Food and Drug Administration) of its investigational drug tazemetostat for the treatment of individuals with relapsed or refractory follicular lymphoma (or FL) who may be with or without EZH2 activating mutations. Epizyme already conducted a meeting with the FDA to discuss the FL registration strategy with the present patient population in the company’s ongoing phase 2 trial. After discussion with the FDA, the company specified the registration strategy for tazemetostat. The company can register patients in both types of EZH2 mutation and patients with wild-type FL with disease progression after two or more lines of therapy. Epizyme expects to submit an NDA (new drug application) to the FDA for the said indications by the fourth quarter of 2019. Epizyme already completed the enrollment of the phase 2 trial for the evaluation of safety and efficacy of tazemetostat for the said indications. Epizyme also anticipates submitting its first NDA to the FDA for tazemetostat for the treatment of individuals with epithelioid sarcoma under accelerated approval pathway in the second quarter of 2019. Epizyme has plans to initiate clinical trials for label expansion of tazemetostat and also evaluate the drug along with other combination therapies. Epizyme sees potential in the drug for the treatment of multiple cancer types. The company plans to initiate the study of tazemetostat for small-cell lung cancer, triple-negative breast cancer, ovarian cancer, and castration-resistant prostate cancer by the second half of 2019. ## Analysts’ recommendations Of the ten analysts tracking Epizyme in January 2019, four of them recommended a “strong buy,” while another four analysts recommended a “buy” rating. Two analysts recommended a “hold” rating for Epizyme in January 2019. The company had a consensus 12-month target price of $19.44, which represents a ~144.84% return on investment over the next 12 months.

  • Why GameStop, Novavax, and Epizyme Jumped Today
    Motley Foollast month

    Why GameStop, Novavax, and Epizyme Jumped Today

    It was a great day for the overall market. Find out why these stocks stood out.

  • Here's Why Epizyme's Shares Are Surging 19.6% Higher Today
    Motley Foollast month

    Here's Why Epizyme's Shares Are Surging 19.6% Higher Today

    A new update on its epigenetics drug, tazemetostat, has kindled investor optimism.

  • ACCESSWIRElast month

    These 4 Healthcare Stocks Are Making Moves

    CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc (SGYP), Novavax Inc (NVAX), and Epizyme Inc (EPZM) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) opened Friday with the Company's shares trading at $0.63 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from early last month.

  • Business Wirelast month

    Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma (FL), both with and without EZH2 activating mutations. The company recently conducted a productive meeting with the U.S. Food and Drug Administration (FDA) to discuss the FL registration strategy based on the current patient population in its ongoing Phase 2 clinical trial.

  • Is Epizyme Inc (EPZM) Going to Burn These Hedge Funds?
    Insider Monkey2 months ago

    Is Epizyme Inc (EPZM) Going to Burn These Hedge Funds?

    “October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being ’08 and the Crash of ’87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]

  • Business Wire2 months ago

    Epizyme Earns $8 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development for First-in-Class PRMT1 Inhibitor

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced it has earned an $8 million milestone payment from GlaxoSmithKline (GSK). The milestone payment follows GSK’s initiation of patient dosing in a Phase 1 clinical trial of GSK3368715, a first-in-class protein arginine methyltransferase1 (PRMT1) inhibitor discovered by Epizyme and licensed to GSK. “We are very pleased to see the progress that GSK has made with its PRMT1 inhibitor program, which marks the second program under our collaboration agreement to enter the clinic,” said Robert Bazemore, president and chief executive officer of Epizyme.

  • Why Is Epizyme (EPZM) Down 11.9% Since Last Earnings Report?
    Zacks2 months ago

    Why Is Epizyme (EPZM) Down 11.9% Since Last Earnings Report?

    Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire3 months ago

    Epizyme Announces Conference Call to Discuss Corporate Updates

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call to discuss corporate updates today at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5172457. Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines.

  • Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3
    Zacks3 months ago

    Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3

    Epizyme (EPZM) incurs narrower-than-expected loss in the third quarter of 2018. The company is on track to submit an NDA for tazemetostat in epithelioid sarcoma in the first half of 2019.

  • Epizyme (EPZM) Reports Q3 Loss, Lags Revenue Estimates
    Zacks3 months ago

    Epizyme (EPZM) Reports Q3 Loss, Lags Revenue Estimates

    Epizyme (EPZM) delivered earnings and revenue surprises of 10.00% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Epizyme: 3Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 54 cents. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment ...

  • Business Wire3 months ago

    Epizyme Reports Third Quarter 2018 Financial Results and Tazemetostat Progress

    Enrollment in Phase 2 Cohort of Follicular Lymphoma Patients with EZH2 Activating Mutations on Track to be Completed by Year End

  • Business Wire4 months ago

    Epizyme Reports Positive Data on Tazemetostat in Epithelioid Sarcoma from its Phase 2 Trial Cohort at ESMO

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced positive interim data from the fully enrolled epithelioid sarcoma cohort of its ongoing Phase 2 study of its lead candidate tazemetostat, a potent, selective, orally available EZH2 inhibitor. The data were presented by the study’s lead investigator, Mrinal Gounder, M.D., attending physician, Sarcoma Medical Oncology and Early Drug Development Services, Memorial Sloan Kettering Cancer Center, during the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany. Interim data as of August 21, 2018 from the 62 patients enrolled show that tazemetostat treatment demonstrated clinically meaningful activity for patients with epithelioid sarcoma (ES).

  • Simply Wall St.4 months ago

    What Kind Of Investor Owns Most Of Epizyme Inc (NASDAQ:EPZM)?

    Every investor in Epizyme Inc (NASDAQ:EPZM) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see insiders Read More...

  • Business Wire4 months ago

    Epizyme to Present Updated Data on Tazemetostat from Full Phase 2 Study Cohort in Epithelioid Sarcoma at ESMO

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of tazemetostat will be presented in a poster discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress to be held October 19-23 in Munich, Germany. Tazemetostat is the company’s potent, selective, orally available, first-in-class EZH2 inhibitor. The Phase 2 study ES cohort completed enrollment in 2017 with a total of 62 patients.

  • Business Wire4 months ago

    Epizyme Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares

    Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the closing of its underwritten public offering of 9,583,334 shares of its common stock at a public offering price of $9.00 per share, which includes 1,250,000 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price less the underwriting discount. The aggregate gross proceeds to Epizyme from the offering, before deducting underwriting discounts and offering expenses, are $86.25 million.

  • Benzinga4 months ago

    The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Boston Scientific Corporation (NYSE: BSX ) Eli Lilly ...

  • CNBC5 months ago

    After-hours buzz: TPX, JCP & more

    Check out the companies making headlines after the bell: Tempur Sealy International TPX shares jumped more than 8 percent in after-hours trading following reports that competitor Mattress Firm is preparing to file for bankruptcy.